Thermo Fisher Scientific Inc.
HealthcareNYSE:TMO · New York Stock Exchange
-$6.09 today
Vol 0.58M · Avg 2.36M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$45.2B of revenue converted into $6.9B of net income for the selected period. Gross margin is 39.4% and net margin is 15.1%, showing how much revenue survives after costs and taxes. EPS is $18.19, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $44.6B +3.9% | $42.9B +0.1% | $42.9B -4.6% | $44.9B +14.5% | $39.2B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $27.8B +10.4% | $25.2B -2.0% | $25.7B -0.9% | $25.9B +32.3% | $19.6B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $16.8B -5.4% | $17.7B +3.1% | $17.2B -9.6% | $19.0B -3.2% | $19.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 37.7% -3.7pp | 41.3% +1.2pp | 40.1% -2.2pp | 42.3% -7.7pp | 50.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $1.4B +0.5% | $1.4B +4.0% | $1.3B -9.1% | $1.5B +4.6% | $1.4B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $7.3B -16.2% | $8.7B +3.2% | $8.4B -6.7% | $9.0B +14.0% | $7.9B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $8.7B -13.9% | $10.1B +3.3% | $9.7B -7.0% | $10.5B +12.6% | $9.3B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.8B -10.6% | $3.1B -8.7% | $3.4B +0.7% | $3.4B +30.4% | $2.6B | $374.2M | $1.2B | $631.8M |
| EBITDA | $11.5B -2.8% | $11.8B +5.4% | $11.2B -6.3% | $11.9B -0.2% | $12.0B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 25.7% -1.8pp | 27.5% +1.4pp | 26.1% -0.5pp | 26.6% -3.9pp | 30.5% | 5.6% | 46.3% | 42.0% |
| Operating Income | $8.1B +5.8% | $7.7B +2.9% | $7.4B -12.7% | $8.5B -17.4% | $10.3B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 18.2% +0.3pp | 17.9% +0.5pp | 17.4% -1.6pp | 19.0% -7.3pp | 26.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $993.0M -7.9% | $1.1B +22.6% | $879.0M +223.2% | $272.0M +532.6% | $43.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $1.4B -14.2% | $1.7B +10.9% | $1.5B +105.4% | $726.0M +35.4% | $536.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$842.0M -26.2% | -$667.0M +44.7% | -$1.2B -40.0% | -$862.0M +41.8% | -$1.5B | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $7.3B +3.9% | $7.0B +12.1% | $6.2B -18.6% | $7.7B -13.3% | $8.8B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 16.3% -0.0pp | 16.3% +1.8pp | 14.6% -2.5pp | 17.1% -5.5pp | 22.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $547.0M -16.7% | $657.0M +131.3% | $284.0M -59.6% | $703.0M -36.6% | $1.1B | $1.3B | -$1.6B | $745.2M |
| Net Income | $6.7B +6.3% | $6.3B +5.7% | $6.0B -13.7% | $7.0B -10.0% | $7.7B | $4.9B | $4.8B | $4.7B |
| Net Margin | 15.1% +0.3pp | 14.8% +0.8pp | 14.0% -1.5pp | 15.5% -4.2pp | 19.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $18 +7.2% | $17 +6.8% | $16 -12.4% | $18 -9.6% | $20 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $18 +7.3% | $17 +7.0% | $15 -12.4% | $18 -9.4% | $19 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $376.0M -1.6% | $382.0M -1.0% | $386.0M -1.5% | $392.0M -0.5% | $394.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $377.0M -1.6% | $383.0M -1.3% | $388.0M -1.5% | $394.0M -0.8% | $397.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.00B
Novartis AG
NYSE:NVS
$292.70B
AstraZeneca PLC
NYSE:AZN
$278.81B
Novo Nordisk A/S
NYSE:NVO
$196.64B
Amgen Inc.
NASDAQ:AMGN
$190.71B
Abbott Laboratories
NYSE:ABT
$152.86B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$144.58B
Danaher Corporation
NYSE:DHR
$127.55B
Agilent Technologies, Inc.
NYSE:A
$36.44B
IQVIA Holdings Inc.
NYSE:IQV
$29.86B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TMO generate?
Thermo Fisher Scientific Inc. (TMO) reported $44.56B of revenue in fiscal 2025.
Is TMO profitable?
Thermo Fisher Scientific Inc. (TMO) reported $6.74B of net income, with a net margin of 15.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.